2-氨基-4-碘嘧啶 | 815610-16-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基-4-碘嘧啶
• 中文别名: 4-碘嘧啶-2-胺
• 英文名称: 4-iodopyrimidin-2-amine
• 英文别名: 2-Amino-4-iodopyrimidine
• CAS: 815610-16-3
• 化学式: C₄H₄IN₃
• mdl: MFCD12406140
• 分子量: 221.0
• InChiKey: YTFBUSIUBSVISR-UHFFFAOYSA-N

物化性质

• 沸点：
  364.9±34.0 °C(Predicted)
• 密度：
  2.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  zinc(II) cyanide 、 2-氨基-4-碘嘧啶 在 四(三苯基膦)钯 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 2.0h， 以75%的产率得到2-氨基-4-氰基嘧啶
  参考文献：
  名称：

  Synthesis and structure–activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors

  摘要：

  The Cell division cycle 7 (Cdc7) protein kinase is essential for DNA replication and maintenance of genome stability. We systematically explored thiazole-based compounds as inhibitors of Cdc7 kinase activity in cancer cells. Our studies resulted in the identification of a potent, selective Cdc7 inhibitor that decreased phosphorylation of the direct substrate MCM2 in vitro and in vivo, and inhibited DNA synthesis and cell viability in vitro.

  DOI：

  10.1016/j.ejmech.2014.04.013
• 作为产物：
  描述：

  2-氨基-4-氯嘧啶 在 氢碘酸 作用下， 以 水 为溶剂， 反应 3.0h， 以95%的产率得到2-氨基-4-碘嘧啶
  参考文献：
  名称：

  Synthesis and structure–activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors

  摘要：

  The Cell division cycle 7 (Cdc7) protein kinase is essential for DNA replication and maintenance of genome stability. We systematically explored thiazole-based compounds as inhibitors of Cdc7 kinase activity in cancer cells. Our studies resulted in the identification of a potent, selective Cdc7 inhibitor that decreased phosphorylation of the direct substrate MCM2 in vitro and in vivo, and inhibited DNA synthesis and cell viability in vitro.

  DOI：

  10.1016/j.ejmech.2014.04.013

文献信息

• [EN] MLKL INHIBITORS<br/>[FR] INHIBITEURS MLKL
  申请人：NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING

  公开号：WO2018157800A1

  公开（公告）日：2018-09-07

  Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.

  嘌呤衍生物，用于抑制细胞坏死性凋亡和/或人类MLKL；包含该衍生物的药物组合物；以及使用有效量的该化合物或组合物治疗MLKL介导的疾病的方法。所述MLKL介导的疾病是与坏死性凋亡相关的病理学，包括缺血再灌注损伤、神经退行性疾病、以及诸如急性胰腺炎、多发性硬化症、炎症性肠病和过敏性结肠炎等炎症性疾病。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005016914A1

  公开（公告）日：2005-02-24

  The present invention discloses pyrimidine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such pyrimidine derivatives are useful in the treatment of diseases associated with inappropriate ErbB family kinase.

  本发明公开了嘧啶衍生物，含有该嘧啶衍生物的组合物和药物，以及制备和使用这些化合物、组合物和药物的方法。这些嘧啶衍生物在治疗与不适当的ErbB家族激酶相关的疾病中很有用。
• Selective and stable base pairing by alkynylated nucleosides featuring a spatially-separated recognition interface
  作者：Hidenori Okamura、Giang Hoang Trinh、Zhuoxin Dong、Yoshiaki Masaki、Kohji Seio、Fumi Nagatsugi

  DOI：10.1093/nar/gkac140

  日期：2022.4.8

  Unnatural base pairs (UBPs) which exhibit a selectivity against pairing with canonical nucleobases provide a powerful tool for the development of nucleic acid-based technologies. As an alternative strategy to the conventional UBP designs, which involve utility of different recognition modes at the Watson–Crick interface, we now report that the exclusive base pairing can be achieved through the spatial

  非天然碱基对 (UBP) 对与标准核碱基配对具有选择性，为开发基于核酸的技术提供了强大的工具。作为传统 UBP 设计的替代策略，其中涉及在 Watson-Crick 界面上使用不同的识别模式，我们现在报告可以通过识别单元的空间分离来实现独家碱基配对。该设计概念通过在其大沟侧具有核碱基样 2-氨基嘧啶或 2-吡啶酮（“假核碱基”）的炔基化嘌呤（NPu，OPu）和哒嗪（NPz，OPz）核苷进行了证明。综合 Tm 测量、2D-NMR 分析和 MD 模拟显示，这些炔基化的嘌呤和哒嗪通过在 DNA 大沟中的假核碱基之间形成互补氢键而表现出独特且稳定的配对特性。此外，炔基化的嘌呤-哒嗪对能够在连续掺入时显着稳定DNA双链体，同时保持高序列特异性。本研究展示了识别界面的分离作为开发新型 UBP 的有前景的策略。
• ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Celgene Corporation

  公开号：US20160009683A1

  公开（公告）日：2016-01-14

  Compounds of formula I for treating, preventing or managing cancer are disclosed. Also disclosed are methods of treating, preventing or managing cancer, such as leukemia, comprising administering the compounds. In certain embodiments, the method of treatment comprise administering a compound provided herein in combination with a second agent. Pharmaceutical compositions and single unit dosage forms comprising the compounds are also disclosed.

  本发明公开了用于治疗、预防或管理癌症的I式化合物。还公开了治疗、预防或管理癌症的方法，例如治疗白血病，包括给予这些化合物。在某些实施例中，治疗方法包括给予本文提供的一种化合物与第二剂量的药物联合使用。还公开了包含这些化合物的制药组合物和单剂量形式。
• Synthesis of (2-Aminopyrimidin-4-yl)(pyridin-4-yl)methanone and Derivatives
  作者：Francis Giraud、Fabrice Anizon、Pascale Moreau、Béatrice Josselin、Sandrine Ruchaud

  DOI：10.1055/a-2107-4571

  日期：2023.11

  Pyrido[3,4-g]quinazoline was previously identified as a relevant scaffold for protein kinase inhibition. In order to assess if the planarity of this heterocyclic system was essential to the protein kinase inhibitory potency observed in this series, new compounds were synthesized and evaluated, in which the central cycle was opened to provide (pyridin-4-yl)(pyrimidin-4-yl)methane derivatives, which were prepared from the corresponding ketone precursor. After preparing (2-aminopyrimidin-4-yl)(pyridin-4-yl)methanone, derivatives were synthesized and evaluated toward a panel of protein kinases. The results demonstrated that the planar pyrido[3,4-g]quinazoline tricyclic system was mandatory to maintain the protein kinase inhibitory potency in this series.

  摘要吡啶并[3,4-g]喹唑啉先前被确定为抑制蛋白激酶的相关支架。为了评估该杂环系统的平面性是否对该系列中观察到的蛋白激酶抑制效力至关重要，我们合成并评估了新的化合物，其中中心循环被打开，以提供(吡啶-4-基)(嘧啶-4-基)甲烷衍生物，这些衍生物是由相应的酮前体制备的。在制备出（2-氨基嘧啶-4-基）(吡啶-4-基)甲酮后，合成了衍生物并对一组蛋白激酶进行了评估。结果表明，平面吡啶并[3,4-g]喹唑啉三环系统是该系列保持蛋白激酶抑制效力的必要条件。